articleJournal of Clinical OncologyMar 30, 2007Closed access

Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

Ludwig Cancer Research

PubMed
Indexed incrossrefpubmed

Abstract

Materials And Methods

We have previously reported a gene expression grade index (GGI), which defines histologic grade based on gene expression profiles. Using this algorithm, we assigned ER-positive BC to either high-or low-genomic grade subgroups and compared these with previously reported ER-positive molecular classifications. As further validation, we classified 666 ER-positive samples into subtypes and assessed their clinical outcome.

Results

Two ER-positive molecular subgroups (high and low genomic grade) could be defined using the GGI. Despite tracking a single biologic pathway, these were highly comparable to the previously described luminal A and B classification and significantly correlated to the risk groups produced using the 21-gene recurrence score. The two subtypes were associated with statistically distinct clinical outcome in both systemically untreated and tamoxifen-treated populations.

Citation impact

838
total citations
FWCI
28.56
Percentile
100%
References
35
Citations per year

Authors

17

Topics & keywords

Keywords
  • Estrogen receptor
  • Tamoxifen
  • Breast cancer
  • Medicine
  • Oncology
  • Internal medicine
  • Estrogen receptor alpha
  • Gene
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.